Display Settings:

Format

Send to:

Choose Destination
Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001.

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Author information

  • 1Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D 60590 Frankfurt am Main, Germany. thaci@em.uni-frankfurt.de

Abstract

Topical calcineurin inhibitors have developed a bad connotation because of a black-box warning that was based on safety concerns of hypothetic systemic absorption and because systemic treatment with calcineurin inhibitors in patients who receive organ transplants is associated with an increased cancer risk. A few case reports of lymphoma and skin cancer in patients treated with topical calcineurin inhibitors initiated the discussion. These drugs were recommended for use as second-line therapy for the short-term and noncontinuous treatment of atopic dermatitis in patients who do not respond adequately to topical corticosteroids or in whom they are contraindicated. According to the latest knowledge, there is no scientific evidence of an increased risk for malignancy due to a topical treatment with calcineurin inhibitors.

Copyright 2010 Elsevier Inc. All rights reserved.

PMID:
20082951
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk